Monthly Archives: June 2020

WCAGY; WRCDF Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Wirecard AG and Encourages Investors to Contact the Firm

NEW YORK, NY / ACCESSWIRE / June 18, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Wirecard AG ("Wirecard" or "the Company") (OTC PINK: WCAGY;WRCDF). Investors who purchased Wirecard securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/wcagy.

The investigation concerns whether Wirecard and certain of its officers and/or directors have violated federal securities laws.

On June 18, 2020, MarketWatch reported that Wirecard's auditor, Ernst & Young, said it did not have sufficient evidence for €1.9 billion euros in cash. Wirecard said "There are indications that spurious balance confirmations had been provided from the side of the trustee." Following this news, Wirecard stock has dropped over 63% during intraday trading on June 18, 2020.

If you are aware of any facts relating to this investigation or purchased Wirecard shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/wcagy. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz and Grossman, LLC

ReleaseID: 594390

Wirecard AG to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / June 18, 2020 / Wirecard AG (OTC PINK:WRCDF) will be discussing their earnings results in their 2019 Second Half Earnings call to be held on June 18, 2020 at 2:00 PM Eastern Time.

To listen to the event live or access a replay of the call – visit
https://www.investornetwork.com/event/presentation/64515

To receive updates for this company you can register by emailing info@investornetwork.com or by clicking get investment info from the company's profile.

About Investor Network

Investor Network (IN) is a financial content community, serving millions of unique investors market information, earnings, commentary and news on what's trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

ReleaseID: 594332

GEO Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of The GEO Group, Inc. and Encourages Investors to Contact the Firm

NEW YORK, NY / ACCESSWIRE / June 18, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of The GEO Group, Inc. ("GEO" or "the Company") (NYSE:GEO). Investors who purchased GEO securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/geo.

The investigation concerns whether GEO and certain of its officers and/or directors have violated federal securities laws.

On June 17, 2020, The Intercept published an article entitled "GEO Group's Blundering Response to the Pandemic Helped Spread Coronavirus in Halfway Houses." The article reported details of a significant COVID-19 outbreak at the Grossman Center, a halfway house in Leavenworth, Kansas operated by GEO Group-which "was for weeks the hardest hit federal halfway house in the country" in terms of confirmed cases of COVID-19. Citing interviews with residents of the Grossman Center, The Interceptcharacterized GEO Group's response as "blundering" and reported "that the virus spread not in spite of the facility's efforts to contain it, but because of it." According to the article, the Grossman Center continued to keep its residents in overcrowded conditions without enforcing personal protective measures even as COVID-19 diagnoses at the facility increased. On this news, GEO Group's stock price fell $1.03 per share, or 7.8%, to close at $12.17 per share on June 17, 2020.

If you are aware of any facts relating to this investigation, or purchased GEO shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/geo. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 594382

Impact of Covid-19 on Hematological Cancers Therapeutics Market 2020 – Revenue Status & Forecast Report 2026

The Hematological Cancers Therapeutics Market Report by Reports and Data provides an extensive overview of the vital elements of the Hematological Cancers Therapeutics market and factors such as drivers, restraints, latest trends, supervisory scenario, competitive landscape, technological advancements, and others.

New York City, United States – June 18, 2020 /MarketersMedia/

According to the current analysis of Reports and Data, the global hematological cancers therapeutics market accounted for USD 31.32 Billion in 2018 and is expected to reach USD 66.34 billion by 2026 , at a CAGR of 9.8 percent. Hematology Cancer Therapeutics market is majorly driven by a high incidence of blood cancer across the globe and favorable funding scenario for the research and development of therapeutics for blood cancer. In terms of region, Asia Pacific is estimated to grow at a CAGR of 10.5 % followed by North America with 9.6% percent.

This is the latest report covering the current COVID-19 scenario. The coronavirus pandemic has greatly affected every aspect of the worldwide industry. It has brought along various changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact are covered in the research report. The report discusses all the major aspects of the market with expert opinions on the current status along with historical data.

Get a sample PDF copy of the report @ https://www.reportsanddata.com/sample-enquiry-form/1068

Key players mentioned in the research report are:
Roche, Celgene, Johnson & Johnson, Karyopharm Therapeutics, Siemens AG, Mindray Medical, Abbott Laboratories, Bio-Rad Laboratories, AbbVie, HemoCue AB, Sysmex, and Novartis.

In terms of applications, the global Hematological Cancers Therapeutics market can be segmented into:
Hospitals
Clinical Laboratories
Academic and Research Institutes
Others

In terms of types, the global Hematological Cancers Therapeutics market can be segmented into:
Pharmacological Therapies
Stem Cell Transplantation
Surgery and Radiation Therapy
Anemia Treatment
Thrombosis Treatment
Neutropenia Treatment
Others

The Hematological Cancers Therapeutics Market is analyzed on the basis of dynamics of demand and supply, pricing, total volume produced, revenue generated, and others. The manufacturing is studied on the basis of several factors such as manufacturing plant distribution, industry production, production capacity, and research and development. It also delivers accurate market evaluations with the use of SWOT analysis, investment analysis, returns analysis, and growth trend analysis, and others.

To get a discount on the report, click @ https://www.reportsanddata.com/discount-enquiry-form/1068

For geographical segmentation, regional supply, application-wise, and type-wise demand, key players, and others, this report covers the following regions: North America, Europe, Asia-Pacific, South America, and Middle East & Africa. The report sheds light on the competitive landscape of the market that covers the product offerings, services, market shares, and business overview. This Hematological Cancers Therapeutics Market research report covers various dynamic aspects like the market drivers, restraints and challenges, and growth prospects. The prominent and leading companies are profiled in the report.

Further key findings from the report suggest
• The market for pharmacological therapies market is projected to grow significantly and deliver a CAGR of 10.5 percent. Owing to pressure for the development of new drugs in lieu of upcoming patent expiries of several drugs by 2026, the leading market players of Hematology Cancer Therapeutics market are focusing on obtaining successful clinical trials to launch new drugs in the market

• The market for hospitals is anticipated to dominate the market with the revenue of 47.6 billion by 2026. Growth in blood cancer therapeutics market for this segment is supported by reimbursement from government as well as private bodies across the globe.

• Asia-Pacific will witness a significant rise at a CAGR of 10.5% from 2018 to 2026 in light of favorable government inclination towards the research and development related to blood cancers. Additionally, government hospital spending and infrastructure development rate across the globe has increased by 7 % during the period 2016-2017, with the majority of the new additions being derived from the Asia Pacific region.

Get the full report description, TOC, Table of Figures, Charts @ https://www.reportsanddata.com/report-detail/hematological-cancers-therapeutics-market

This research report delivers a 360 overview of the competitive landscape of the Global Hematological Cancers Therapeutics Market. Furthermore, it includes massive data regarding the latest trends, technological advancements, and methodologies. The study analyzes the Global Hematological Cancers Therapeutics Market in a detailed and extensive manner for the readers to gain better insights.

Thank you for reading our report. For further details or to inquire about customization, please let us know and we will offer you the report as per your needs.

About Us:
Our in-house experts assist our clients with advice based on their proficiency in the market that helps them in creating a compendious database for the clients. Our team offers expert insights to clients to guide them through their business ventures. We put in rigorous efforts to keep our clientele satisfied and focus on fulfilling their demands to make sure that the end-product is what they desire. We excel in diverse fields of the market and with our services extending to competitive analysis, research and development analysis, and demand estimation among others, we can help you invest your funds in the most beneficial areas for research and development.

Contact Info:
Name: John Watson
Email: Send Email
Organization: Reports And Data
Address: 40 Wall St. 28th floor New York City, NY 10005 United States
Phone: +1-212-710-1370
Website: https://www.reportsanddata.com/

Source URL: https://marketersmedia.com/impact-of-covid-19-on-hematological-cancers-therapeutics-market-2020-revenue-status-forecast-report-2026/88964186

Source: MarketersMedia

Release ID: 88964186

Formaldehyde Market Growth, Analysis and Industry Forecast 2020-2027 | Reports And Data

An extensive study of the product application and services conducted by subject matter experts assessing the Formaldehyde Market will help product owners to make a wise decision.

New York, United States – June 18, 2020 /MarketersMedia/

The Formaldehyde Market has observed unceasing growth in the past few years and has prospects to grow even further during the forecast period (2020-2027). The study provides a comprehensive view and insights, highlighting the key outcomes of the industry. These insights help interested individuals or individuals to frame better business strategies and make informed decisions for superior profitability. Moreover, the forecast aids venture or private players, in assessing the companies and taking the best available route to optimize their options.

The report covers all the intricate details of the Formaldehyde market and how it has fared in the past. Using historical data, an accurate forecast is derived in the report, which will be beneficial to all the users and entities interested in the Formaldehyde market.

This report covers the recent COVID-19 incidence and its impact on Formaldehyde. The pandemic has widely affected the economic scenario. This study assesses the current landscape of the ever-evolving business sector and the present and future effects of COVID-19 on the market.

Get a Free sample report with revised and up-to-date graphs @ https://www.reportsanddata.com/sample-enquiry-form/1709

Key Participants of the Formaldehyde Market are:
BASF SE, Celanese AG, Dynea AS, Alder S.p.A, Foremark Performance Chemicals, Georgia-Pacific Chemicals LLC, Huntsman International LLC, Johnson Matthey Process Technologies, Momentive Specialty Chemical Inc., Perstorp Orgnr
The Formaldehyde segments and market characteristics are mentioned below:

By Type – Urea Formaldehyde
• Phenol Formaldehyde
• Melamine Formaldehyde
• Polyoxymethylene
• Others.

Market has been divided by End-User as:
• Automotive
• Construction
• Furniture
• Healthcare
• Others

Market segmentation of the Formaldehyde Industry based on Geographical Break-down: North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.

For readers interested in the Formaldehyde Industry, this report will serve as an exhaustive database, giving the user a comprehensive outlook. Keeping oneself updated with the market changes and key players is crucial. Customization of reports according to individual needs based on region, key participants, and type is available.
For the consumer-driven market, sperate analysis can be included and customized with respect to age, gender, occupation, income level or education, etc.

Consumer patterns
* Purchasing patterns (comfort & convenience, economical, pride)
* Purchasing behavior (seasonal, usage rate)
* Lifestyle (health-conscious, family orientated, community active)
* Outlooks (service, quality, risk, influence)

Any Query or Discount? Ask our Expert @ https://www.reportsanddata.com/discount-enquiry-form/1709

Key segments of the report:
• Formaldehyde Market Summary
• Monetary effect on the economy
• Formaldehyde Market competition
• Formaldehyde Market analysis by application
• Industrial chain, chain of buyers, and sourcing strategy
• Distributors/traders, marketing strategy analysis
• Different types of markets, market effect, diagnosis
• Market forecast
• Recent updates, product portfolio, demographics, geographical segmentation, and regulatory framework of the Global Formaldehyde Market are included in the report

Strategic Points Covered in Table of Content of Formaldehyde Market:
Chapter 1: Executive Summary
Chapter 2: Abbreviation and Acronyms
Chapter 3: Preface
3.1 Research Scope
3.2 Research Methodology
3.2.1 Primary Sources
3.2.2 Secondary Sources
3.2.3 Assumptions
Chapter 4: Market Landscape
4.1 Market Overview
4.2 Classification/Types
4.3 Application/End Users
Chapter 5: Market Trend Analysis
5.1 Introduction
5.2 Drivers
5.3 Restraints
5.4 Opportunities
5.5 Threats
Chapter 6: Industry Chain Analysis
6.1 Upstream/Suppliers Analysis
6.2 “Regulatory Affairs Outsourcing.” Analysis
6.2.1 Technology Analysis
6.2.2 Cost Analysis
6.2.3 Market Channel Analysis
6.3 Downstream Buyers/End Users

Uses of this Report:
• This report gives an up-to-date view of the Global Formaldehyde Market
• Gives forecast with current market regulations put on the market and how it will affect the market’s future.
• It provides a six-year forecast based on how the market is expected to grow
• It helps in understanding the key product segments and their prospects
• It provides a detailed analysis of changing competition dynamics and gives you a head start.
• It enables one to make better business decisions by having complete insights of market and by making meticulous findings for markets prospects.
• PESTEL analysis of the market in the five major regions.

Why trust Reports and Data’s analytical insights?
• Easy explanation of complex market research methodologies.
• Focuses on delivering top-quality market reports
• Assisted the growth of over 500+ clients
• 24-hour customer support for clients across different geographies
• A systematic and methodical approach at all stages of the market research process

Read the Comprehensive Report with a meticulous TOC and panoramic coverage of the market @ https://www.reportsanddata.com/report-detail/formaldehyde-market

Report Customization:
Reports and Data also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Contact Info:
Name: John Watson
Email: Send Email
Organization: Reports And Data
Address: 40 Wall St. 28th floor New York City, NY 10005 United States
Phone: +1-212-710-1370
Website: https://www.reportsanddata.com/

Source URL: https://marketersmedia.com/formaldehyde-market-growth-analysis-and-industry-forecast-2020-2027-reports-and-data/88964190

Source: MarketersMedia

Release ID: 88964190

ENPH Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Enphase Energy, Inc. and Encourages Investors to Contact the Firm

NEW YORK, NY / ACCESSWIRE / June 18, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Enphase Energy, Inc.

("Enphase" or "the Company") (NASDAQ:ENPH). Investors who purchased Enphase securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/enph.

The investigation concerns whether Enphase and certain of its officers and/or directors have violated federal securities laws.

On June 17, 2020, Prescient Point Capital Management published an article alleging that Enphase fabricated over $205.3 million, or 39%, of its reported U.S. revenue. The report continues to allege several more falsified and/or misleading business practices, including that the company reported nearly impossible reduction in its unit costs and how executives and board members recently dumped stocks.

If you are aware of any facts relating to this investigation or purchased Enphase shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/enph. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz and Grossman, LLC

ReleaseID: 594375

CODX INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action Against Co-Diagnostics, Inc. and Encourages Investors to Contact the Firm

NEW YORK, NY / ACCESSWIRE / June 18, 2020 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Co-Diagnostics, Inc. ("Co-Diagnostics" or the "Company") (NASDAQ:CODX) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Co-Diagnostics securities between February 25, 2020 and May 15, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/codx.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that Defendants made continual, knowing, and willful misstatements about their main product, a COVID-19 diagnostic test, to pump up the price of Co-Diagnostics, Inc.'s stock while the officers and directors exercised low priced options and dumped their stock into the market. Their fraudulent misstatements, and disregard for the basic scientific principles that make their falsity of their statements clear in retrospect, caused investors to lose millions of dollars.

A class-action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: www.bgandg.com/codx, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Co-Diagnostics, you have until August 17, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 594083

LAWSUIT FILED: Block & Leviton LLP Announces that it Filed a Lawsuit Against Enphase Energy, Inc. for Securities Fraud; Investors Who Lost Money Should Contact the Firm

BOSTON, MA / ACCESSWIRE / June 18, 2020 / Block & Leviton LLP (www.blockesq.com), a national securities litigation firm, announces that it has filed a class action lawsuit on behalf of shareholders against Enphase Energy, Inc. (NASDAQ:ENPH) and certain of its officers for securities fraud. The lead plaintiff deadline is August 17, 2020. Investors who purchased Enphase Energy shares between February 26, 2019 and June 17, 2020 are encouraged to contact the firm for a free case evaluation.

On June 17, 2020, Prescience Point Capital Management published a report concerning Enphase Energy, in which Prescience Point wrote that "[a]t least $205.3m of ENPH's reported FY19 US revenue is fabricated, and a significant portion of its international revenue is fabricated as well." Prescience Point further wrote that "Deloitte should launch an in-depth investigation of ENPH's accounting practices," and set a target price of "Delisted" for ENPH. Prescience Point also detailed hundreds of millions of dollars' worth of insider sales in the last few months. On this news, the stock fell approximately 26% from its June 16, 2020 closing price.

The lawsuit, filed in the Northern District of California, alleges that Enphase misrepresented and/or failed to disclose to investors that: (1) its revenues, both U.S. and international, were inflated; (2) the Company engaged in improper deferred revenue accounting practices; (3) the Company's reported base points expansion in gross margins were overstated; and that (4) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times. The case is captioned Hurst v. Enphase Energy, Inc., No. 5:20-cv-04036 (N.D. Cal.).

If you purchased or acquired shares of Enphase Energy and have questions about your legal rights or possess information relevant to this matter, please contact Block & Leviton attorneys at (617) 398-5600, via email at cases@blockesq.com, or at https://shareholder.law/enph.

Block & Leviton LLP is a firm dedicated to representing investors and maintaining the integrity of the country's financial markets. The firm represents many of the nation's largest institutional investors as well as individual investors in securities litigation throughout the United States. The firm's lawyers have recovered billions of dollars for its clients.

This notice may constitute attorney advertising.

CONTACT:

BLOCK & LEVITON LLP
260 Franklin St., Suite 1860
Boston, MA 02110
Phone: (617) 398-5600
Email: cases@blockesq.com
www.blockesq.com

SOURCE: Block & Leviton LLP

ReleaseID: 594356

Wrap Technologies Announces New International Purchase Orders

Orders from Three Countries for Over 200 BolaWrap Devices, 2,600 Cartridges and Accessories

TEMPE, AZ / ACCESSWIRE / June 18, 2020 / Wrap Technologies, Inc. (the "Company" or "Wrap") (NASDAQ:WRTC), an innovator of modern policing solutions, today announced the Company has received new international purchase orders from three countries in Asia for over 200 BolaWrap devices, more than 2,600 cartridges and accessories. Two purchase orders are follow-on orders from demonstrations and trainings conducted last year. The third purchase order is an initial order from a new country beginning BolaWrap demonstrations and trials this year.

"We are excited about our continued international growth with BolaWrap being purchased by the 27th country," said Tom Smith, President of Wrap Technologies. "It is also encouraging to see countries test and evaluate BolaWrap and then place follow-on orders, reflecting their appreciation and demand for our remote restraint solution."

Wrap expects to recognize the revenue on these orders in Q2 of 2020.

About Wrap Technologies (NASDAQ:WRTC)

Wrap Technologies is an innovator of modern policing solutions. The Company's BolaWrap 100 product is a patented, hand-held remote restraint device that discharges an eight-foot bola style Kevlar® tether to restrain an individual at a range of 10-25 feet. Developed by award winning inventor Elwood Norris, the Company's Chief Technology Officer, the small but powerful BolaWrap 100 assists law enforcement to safely and effectively control encounters, especially those involving an individual experiencing a mental crisis. For information on the Company please visit www.wraptechnologies.com. Examples of recent media coverage are available as links under the "Media" tab of the website.

Trademark Information: BolaWrap and Wrap are trademarks of Wrap Technologies, Inc. All other trade names used herein are either trademarks or registered trademarks of the respective holders.

Cautionary Note on Forward-Looking Statements – Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding the Company's overall business, total addressable market and expectations regarding future sales and expenses. Words such as "expect," "anticipate," "should," "believe," "target," "project," "goals," "estimate," "potential," "predict," "may," "will," "could," "intend," variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company's control. The Company's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: the Company's ability to successful implement training programs for the use of its products; the Company's ability to manufacture and produce product for its customers; the Company's ability to develop sales for its new product solution; the acceptance of existing and future products; the availability of funding to continue to finance operations; the complexity, expense and time associated with sales to law enforcement and government entities; the lengthy evaluation and sales cycle for the Company's product solution; product defects; litigation risks from alleged product-related injuries; risks of government regulations; the business impact of health crises or outbreaks of disease, such as epidemics or pandemics; the ability to obtain export licenses for counties outside of the US; the ability to obtain patents and defend IP against competitors; the impact of competitive products and solutions; and the Company's ability to maintain and enhance its brand, as well as other risk factors included in the Company's most recent annual report on Form 10-K, quarterly report on Form 10-Q and other SEC filings. These forward-looking statements are made as of the date of this press release and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

WRAP TECHNOLOGIES CONTACT:
Paul M. Manley
VP – Investor Relations
612-834-1804
pmanley@wraptechnologies.com

SOURCE: Wrap Technologies, Inc.

ReleaseID: 594344

VIRATECH CORP Announces My Body Symphony CEO Letter Update to Shareholders

My Body Symphony completes facility expansion and launch of new product lines.

SARASOTA, FL / ACCESSWIRE / June 18, 2020 / VIRATECH CORP (OTC PINK:VIRA) announces today their subsidiary Body Symphony CEO, Dr. Max MacCloud update letter to shareholders.

Valued Shareholder,

Throughout the last year, Body Symphony has been working extensively with product research and development, forming new strategic alliances, capabilities and expanding our production capacity. I am extremely proud of these accomplishments, our history, and recent breakthroughs producing and marketing products that positively impact peoples' health and in turn, the quality of their lives. The current conditions are unprecedented and highlight the need for all of us to actively maintain and improve our health. So, I also wish to take this opportunity to recognize and thank the many teams of people on the frontlines that are supporting our country in various capacities during these challenging and confusing times.

We are extremely excited to announce the three newest My Body Symphony products just being completed and/or recently launched:

Liposomal Vitamin C. Vitamin C is one of the most important nutrients that our body needs each and every day. Our Liposomal Vitamin C allows high doses of Vitamin C that will enter the cell even more efficiently than Vitamin C delivered intravenously. The RDA (Recommended Daily Allowance) is ridiculously low and there are hundreds of excellent studies and many years of clinical experience that support the benefits of regularly taking many times the RDA recommended amount. A major limitation, however, is absorption and uncomfortable GI side-effects. High dosages of oral Vitamin C are easily accomplished using our Lipo-C, due to the phospholipids used to surround & encapsulate the vitamin C, thereby allowing for more efficient absorption and providing unparalleled support to the immune system and detoxification pathways.
RHMEDY. This is a ‘high-performance upgrade to one's daily hygiene practices.' Using this safe and natural ‘antiseptic solution' to irrigate the sinuses and nasal passages, it provides a major enhancement to a person's ability to fend off assaults from various irritants and pathogens. Although we make no medical or health claims since it is not a medication, there are numerous physicians that do. This product is particularly relevant given our current pandemic.
Carbon 60 in Organic-Certified Pumpkin Seed Oil. C60 has been heralded as potentially the biggest health breakthrough EVER! It contains 60 Carbon atoms, hence "Carbon 60", is a unique soccer ball shape providing powerful antioxidant and detoxification properties. Carbon 60 was so revolutionary it earned the Nobel Prize for the scientist who first discovered it. It fights free radicals in the body and studies are showing a wide range of benefits from detoxification to anti-aging to enhanced brain health and improved immune system functioning. We are extremely proud of our Carbon 60 in certified pumpkin seed oil (PSO) which is the world's most-nutritious & best-tasting oil. PSO has been shown to lower cholesterol, promote heart health, assist with prevention of baldness & restoration of hair growth, reduce enlarged prostates, and contain anti-inflammatory properties.

With the expansion of our facilities and the aggressive approach we have taken on by pursuing and developing new, innovative products, we feel that Body Symphony & Viratech are well positioned to create value in our respective categories. I can not emphasize enough the importance of Carbon 60. It is such a new breakthrough to the health and supplement community, and it provides multiple unique opportunities to My Body Symphony specifically being paired with pumpkin seed oil. Carbon 60 may well be the most important health discovery ever.

Our focus since inception has been to compile great products under an innovative brand that provides shareholder value for long term growth while providing exceptional health benefits through a variety of great-tasting options that are easy to integrate into any routine. The operational changes made have allowed for more efficient development, testing, as well as an overall reduction in time-to-market. I am very excited to deliver additional updates along with the introduction of new complementary product lines over the coming months.

Yours in Health,

Dr. Max MacCloud, DO, ND, PhD, CEO

Please visit our web sites and follow us on social media:
www.mybodysymphony.com

SOCIAL MEDIA:

Facebook and Instagram
MyBodySymphony

The statements made regarding these products have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease. All information presented here is not meant as a substitute for or alternative to information from health care practitioners. The Federal Food, Drug, and Cosmetic Act requires this notice.

About Body Symphony:

Originally founded in 2009 with operations in Sarasota, Florida, Body Symphony is now a subsidiary of a publicly traded holding company (Viratech). Body Symphony develops, manufactures, and markets innovative nutritional and health-supporting products to the general health-conscious, sports, fitness, and nutrition markets. The Company plans on continuing to extend and deepen its product lines to include other progressive market segments through acquisitions and organic growth of existing product lines. www.mybodysymphony.com

About VIRATECH CORP:

Viratech Corp. is a publicly traded holding company (OTC: VIRA) focused on acquisitions in health, wellness, and nutrition with operations in San Diego, CA, Atlanta, GA, and Florida. Viratech subsidiaries include; Cambridge Golf a company that designs and manufactures innovative sporting goods, clothing, supplements, CBD/hemp products and accessories to the sports, nutrition and golf markets; Medori Wellness producing the highest quality and purest CDB products to improve the lifestyle and well-being of its customers and My Body Symphony a company developing, producing and marketing healthy, organic, plant-based products that can and will make a difference in people's lives. Viratech will continue to foster organic growth within its current holdings as well as grow through strategic acquisitions. Information on all Viratech holdings is available through the Cambridge Golf website. www.cambridgegolfing.com.

Please also visit: www.medoriwellnes.com

Safe Harbor: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contact Information:

Henry Manayan, President/CEO
Henry@cambridgegolfing.com

SOURCE: Viratech Corp.

ReleaseID: 594270